Abstract 297P
Background
Radiotherapy and chemotherapy, or a combination of both have a significant role in the management of cervical cancer. In order to reduce the burden of cervical cancer in a tangible way especially in Indonesia, the need for both modalities demand must be assessed. Considering this, it is necessary to discuss and determine the calculation of the optimal and actual Radiotherapy and Chemotherapy Utilization Rate (RUR and CUR), also the unmet need (gap) between the two rates for cervical cancer in Indonesia.
Methods
Descriptive study of cross-sectional design, total sampling method by taking secondary data from cancer registries and/or internal medical records of participating hospitals with radiotherapy centres in Indonesia in 2019. Data were then separated into hospital data (all cervical cancer cases in the hospital) and RT data (cases from radiotherapy department only).
Results
The total data from the 33 participating hospitals was 4937, divided into 3617 hospital data and 1320 RT data.
The average age of patients was 48-52 years (7-91 years). Patient domicile was mostly from Java Island. Stage III was the most common stage (39.4%). Cervical cancer management was dominated by radiotherapy alone and chemoradiation (28.5% and 27.4%).
Optimal rates can only be based on hospital data that have complete stage attributes.
The optimal, actual RUR and unmet need values were 97.2% (90.9-97.4%), 61.24%, and 36.7% (32.62-37.13%), respectively.
For CUR, the optimal, actual and unmet need values were 87.8% (81-88%), 40%, 54.5% (50.8-55%), respectively.
The actual RUR and CUR for combined data were 70.93% and 39.6%, respectively.
Conclusions
The optimal and actual values of RUR and CUR for cervical cancer in Indonesia still have a large gap, indicating more need for demand of both modalities.
Efforts are needed to increase the actualization of RUR and CUR closer to their optimal rate. Factors affecting RUR and CUR should be explored universally including the patient, clinician, and healthcare system aspects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract